Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

NCT07631884 is registered in ClinicalTrials.gov with Haihua Yuan as lead sponsor.

NCT NCT07631884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07631884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Lead sponsor
Haihua Yuan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 15, 2026
Completion date
December 31, 2028
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, biliary tract neoplasms, cervical neoplasms, colorectal neoplasms, endometrial neoplasms, gastric neoplasms, head and neck neoplasms, her2 expression, locally advanced malignant solid neoplasm, metastatic malignant solid neoplasm, neoplasms (cancer / tumors), non-small cell lung carcinoma (nsclc), pancreatic neoplasms, solid tumors, unresectable malignant solid neoplasm, urothelial carcinoma (uc)